IO Biotech, Inc. (IOBT)
NASDAQ: IOBT · Real-Time Price · USD
0.697
+0.019 (2.74%)
At close: Dec 5, 2025, 4:00 PM EST
0.714
+0.017 (2.45%)
After-hours: Dec 5, 2025, 7:59 PM EST
IO Biotech Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for IO Biotech stock have an average target of 3.50, with a low estimate of 3.00 and a high estimate of 4.00. The average target predicts an increase of 402.37% from the current stock price of 0.70.
Analyst Consensus: Buy
* Price targets were last updated on Oct 22, 2025.
Analyst Ratings
The average analyst rating for IO Biotech stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 1 | 2 | 2 | 2 |
| Hold | 0 | 0 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $10 → $3 | Buy | Maintains | $10 → $3 | +330.60% | Oct 22, 2025 |
| TD Cowen | TD Cowen | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Sep 30, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Sep 29, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $6 → $4 | Buy | Maintains | $6 → $4 | +474.14% | Aug 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +1,622.41% | Apr 1, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
11.02M
EPS This Year
-1.19
from -1.45
EPS Next Year
-0.45
from -1.19
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | 31.2M | ||||
| Avg | n/a | 11.0M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.00 | -0.19 | |
| Avg | -1.19 | -0.45 | |
| Low | -1.27 | -0.65 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.